Complement Therapeutics Secures €72 Million In Series A Financing To Advance Novel Therapies Targeting Complement-Mediated Diseases
Apr 17, 2023•over 2 years ago
Amount Raised
€72 Million
Round Type
series a
Investors
Seroba Life SciencesHadean VenturesCambridge Innovation CapitalPanakès PartnersBio Generation VenturesForbionGimv
Description
Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, today announced the completion of a €72 million Series A financing. The round was led by Gimv, a Belgian-based private equity and venture capital fund, co-led by Forbion as existing investor and further joined by BioGeneration Ventures (BGV), Panakès Partners, Cambridge Innovation Capital (CIC), Hadean Ventures and Seroba Life Sciences.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech